Signal from the log
ReEmerge
37 M$ · Series A · United States · Medtech
ReEmerge sort de l'ombre avec un dispositif implanté qui stimule le thalamus central pour remettre en marche des circuits cérébraux affaiblis. Il vise les troubles cognitifs durables qui suivent un traumatisme crânien, quand la rééducation demande au patient de compenser au lieu de restaurer. Le tour finance une étude clinique.
Article
Announced on , logged by the watch of 15 September 2026.
- Operation
- Funding round
- Announced amount
- 37 M$
- Stage
- Series A
- Country
- United States
- Sector
- Medtech
What the log says
Editorial note, in French
Sujet traité. L'article donne les sources et la position de Bolus.
The investors
Led by U.S. Venture Partners , Santé Ventures , with Oxford Science Enterprises , 415 Capital , IAG Capital Partners , The Vertical Group , Dendrion Ventures
Provenance
Source prnewswire
Logged on 15 September 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Article The operation led to an article, with its sources checked one by one.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.